Subscribe to RSS
Auditive and Vestibular Changes Related to the Use of Hydroxychlorochine and Chlorochine: An Integrative Review[*]Funding Financial support by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brazil (CAPES) – Finance Code 001.
Introduction The use of hydroxychloroquine and chloroquine is formally indicated in cases of chronic autoimmune diseases. However, the use of these medications has already been associated with possible transitory or definitive alterations in hearing function and/or vestibular function in humans, when administrated in the short and long terms.
Objective To describe, through a literature analysis, the functional vestibular and/or hearing alterations, caused by the use of hydroxychloroquine and chloroquine in youths and adults.
Data Synthesis In total, 2,481 studies were identified in the initial search: out of these 32 were selected for a full-text reading, and 9 were selected after the exclusion of those which did not meet the eligibility criteria. Of these, four articles pointed to the presence of vestibular and auditory-associated alterations, three indicated only auditory pathologies, and two, vestibular disorders. Regarding the auditory alterations, tinnitus was the most frequent symptom, and bilateral sensorineural hearing loss was described in most studies, varying in degree from mild to severe. As for the vestibular alterations, vertigo was the most reported symptom.
Conclusion Knowledge of the auditory and vestibular effects after the use of these substances can help in the decision regarding the best treatment, enabling the consideration of other available therapies for patients at risk of suffering those alterations, reducing the risk of auditory and vestibular disorders.
* Work performed at the Speech Therapy Department, Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil.
Received: 22 August 2020
Accepted: 08 November 2020
29 March 2021 (online)
© 2021. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 Word Health Organization. 2020 Novel Coronavirus (2019-nCoV) Situation report - 1. [Internet]. . Accessed in 2020 apr 21 from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
- 2 Word Health Organization. 2020 Novel Coronavirus (2019-nCoV) Situation report - 22. [Internet]. . Accessed in 2020 apr 11 from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2
- 3 Word Health Organization. 2020 Coronavirus disease (COVID-19) Situation report - 51. [Internet]. . Accessed in Mar 11 from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10
- 4 Word Health Organization. 2020 Coronavirus disease (COVID-19) Situation report - 131. [Internet]. . Accessed in May 30 from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200530-covid-19-sitrep-131.pdf?sfvrsn=d31ba4b3_2
- 5 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506 DOI: 10.1016/S0140-6736(20)30183-5.
- 6 Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 2020; 35 (05) 1545-1549 DOI: 10.1007/s11606-020-05762-w.
- 7 Sung-sun K. 2020 Physicians work out treatment guidelines for coronavirus. [Internet]. . Accessed in 2020 mar 19 from: m.koreabiomed.com/news/articleView.html?idxno=7428
- 8 Yao X, Ye F, Zhang M. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71 (15) 732-739 DOI: 10.1093/cid/ciaa237.
- 9 China Law Translate. 2020 Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition). [Internet]. . Accessed in 2020 Mar 4 from: https://www.chinalawtranslate.com/coronavirus-treatment-plan-7/
- 10 National Health Surveillance Agency. (ANVISA). 2020 Clarifications on hydroxychloroquine and chloroquine. [Internet]. . Accessed in 2020 Mar 19 from: http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/content/covid-19-esclarecimentos-sobrehidroxicloroquina-e-cloroquina/219201
- 11 Ahn DG, Shin HJ, Kim MH. et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020; 30 (03) 313-324 DOI: 10.4014/jmb.2003.03011.
- 12 Jin Y, Yang H, Ji W. et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020; 12 (04) E372 DOI: 10.3390/v12040372.
- 13 Lacava AC. Complicações oculares da terapêutica com a cloroquina e derivados. Arq Bras Oftalmol 2010; 73 (04) 384-389
- 14 Figueiredo MC, Atherino CCCT, Monteiro CV, Levy RA. Antimaláricos e Ototoxicidade. Rev Bras Reumatol 2004; 44 (03) 212-214
- 15 Dwivedi GS, Mehra YN. Ototoxicity of chloroquine phosphate. A case report. J Laryngol Otol 1978; 92 (08) 701-703 DOI: 10.1017/s0022215100085960.
- 16 Fernandes MRN, Soares DBR, Thien CI, Carneiro S. Hydroxychloroquine ototoxicity in a patient with systemic lupus erythematosus. An Bras Dermatol 2018; 93 (03) 469-470 DOI: 10.1590/abd1806-4841.20187615.
- 17 Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. [Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database]. Rev Med Interne 2017; 38 (05) 340-343 DOI: 10.1016/j.revmed.2016.07.008.
- 18 Khalili H, Dastan F, Dehghan Manshadi SA. A case report of hearing loss post use of hydroxychloroquine in a HIV-infected patient. Daru 2014; 22 (01) 20
- 19 Jourde-Chiche N, Mancini J, Dagher N. et al. Antimalarial ototoxicity: an underdiagnosed complication? A study of spontaneous reports to the French Pharmacovigilance Network. Ann Rheum Dis 2012; 71 (09) 1586 DOI: 10.1136/annrheumdis-2011-201265.
- 20 Prince DS, Hardin JG. Hydroxychloroquine-induced vertigo. JAMA 1975; 233 (09) 984
- 21 Gustafsson LL, Walker O, Alván G. et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983; 15 (04) 471-479 DOI: 10.1111/j.1365-2125.1983.tb01532.x.
- 22 Bernard P. Alterations of auditory evoked potentials during the course of chloroquine treatment. Acta Otolaryngol 1985; 99 (3-4): 387-392 DOI: 10.3109/00016488509108928.
- 23 Seçkin U, Ozoran K, Ikinciogullari A, Borman P, Bostan EE. Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis. Rheumatol Int 2000; 19 (05) 203-204
- 24 Cox RM. Waiting for evidence-based practice for your hearing aid fittings? It's here!. Hear J 2004; 57 (08) 10-17 DOI: 10.1097/01.HJ.0000292854.24590.8d.